News Releases
-
APIs
Bachem Enters Strategic Collaboration With Lilly To Manufacture Oligonucleotide-Based Drug Substance
Bachem will provide the appropriate engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology.Released by: Bachem
-
No More DMF: Greener Solid-Phase Peptide Synthesis With Binary Solvents
Register now for the webinar on Thursday, May 12th at 5:30pm CET / 8:30am PST.Released by: Bachem
-
APIs
WEBINAR: The Use of Enzymes in the Production of Peptide API
Learn in this webinar how enzymes enable greener peptide syntheses and what questions appear around the use of enzymes in a GMP setting.Released by: Bachem
-
Emergent Secures Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate
Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021.Released by: Emergent CDMO
-
IDT Biologika is increasing its production capacity of vaccines
Saxony-Anhalt's Prime Minister Reiner Haseloff visited the new facilitiesReleased by: IDT Biologika
-
IDT Biologika on the Production of Inactivated COVID-19 Vaccine
Valneva and IDT Biologika Announce Collaboration for Production of Inactivated COVID-19 Vaccine VLA2001Released by: IDT Biologika
-
BACHEM LAYS FOUNDATIONS FOR COMPANY’S LARGEST PRODUCTION BUILDING ON SWISS NATIONAL FUTURE DAY
...Released by: Bachem
-
Clinical Trial Materials
Pharmather Engages Alcami For Clinical And Commercial Manufacturing Of Novel Ketamine Products
Alcami to manufacture PharmaTher’s proprietary ketamine products for FDA Phase 3 clinical studies and global commercialization.Released by: Alcami
-
Promotions & Moves
Alcami Announces Parenteral Operations Leadership Appointments
Chad Bovero, James Fife, and Tobin Cowart promoted to senior leadership team.Released by: Alcami
-
Promotions & Moves
Alcami Appoints Timothy Compton As Chief Business Officer
25-year industry professional brings a track record of leading high-performing, client-centered business teams.Released by: Alcami
-
Drug Development | Formulation Development
Alcami Expands Parenteral Operations With Additional Investment
A $31 million investment will expand its sterile development and manufacturing operation in Charleston, SC.Released by: Alcami
-
-
Bachem reports excellent results for the first half-year 2021
Sales of CHF 500 million are now expected for the year 2021.Released by: Bachem
-
APIs
Propofol – A Bachem Success Story
The COVID-19 pandemic has rapidly expanded awareness of the API Propofol, produced by Bachem in Vionnaz.Released by: Bachem
-
Bachem and Novo Nordisk Redesign SPPS for Green Chemistry
Replacing gold standard solvents to provide a greener alternative.Released by: Bachem
-
Bachem News & Events
Learn more about what is happening at Bachem, what activities we have coming up, and what events you can meet us both virtually and in-person.Released by: Bachem
-
Analytical Services | Biologics, Proteins, Vaccines | Extractables and Leachables
On-Demand Lab Open House
Sign up to get a close-up look at our US network of laboratories and hear about our expansion plans.Released by: Alcami
-
Formulation Development
Tryp Therapeutics Partners with Alcami for Proprietary Formulations
The agreement represents another step toward the proprietary manufacturing, formulation, and delivery of products for Tryp’s PFNTM program.Released by: Alcami
-
Microbiology
On-Demand Webinar: Microbial In-Use Studies
In this webinar, Alcami’s Brent Harlow will guide you through the necessity of these studies and how to successfully perform them for FDA approval.Released by: Alcami
-
Tablet Development Process Training - July 20-21
This course provides comprehensive insight into the tablet development process to provide powerful tools that you can put to work immediately.Released by: Federal Equipment Company
